A pioneering clinical trial in Japan reveals that stem cell-derived dopamine neurons can survive, function, and boost movement in Parkinson’s patients, without triggering serious side effects or abnormal growth.
In a recent study in the journal Nature, researchers in Japan report the results of a Phase I/II clinical trial using bilateral transplantation of induced pluripotent stem (iPS)-cell-derived dopaminergic progenitors to treat Parkinson’s disease (PD). The study examined the safety and effectiveness of this cell therapy in seven patients with PD aged 50–69.
Study findings revealed the therapy’s relative safety, with no serious adverse events, including death or hospitalization, reported. While motor symptoms improved by an average of 20.4% during medication-free (OFF) periods and 35.7% during medicated (ON) periods at 24 months, these gains were not uniform: four of six patients showed OFF-period improvements, and five of six improved during ON periods.
please visit this official website more information about Parkinson’s Disease: symptoms, how to diagnose and treat it..
